- Home
- FBIO vs BIVI Comparison
FBIO vs BIVI Comparison
Compare FBIO & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIO
- BIVI
- Stock Information
- Founded
- FBIO 2006
- BIVI 2013
- Country
- FBIO United States
- BIVI United States
- Employees
- FBIO N/A
- BIVI N/A
- Industry
- FBIO Biotechnology: Pharmaceutical Preparations
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- FBIO Health Care
- BIVI Health Care
- Exchange
- FBIO Nasdaq
- BIVI Nasdaq
- Market Cap
- FBIO 39.4M
- BIVI 45.1M
- IPO Year
- FBIO N/A
- BIVI N/A
- Fundamental
- Price
- FBIO $1.43
- BIVI $3.19
- Analyst Decision
- FBIO Strong Buy
- BIVI Strong Buy
- Analyst Count
- FBIO 4
- BIVI 2
- Target Price
- FBIO $16.33
- BIVI $40.00
- AVG Volume (30 Days)
- FBIO 605.0K
- BIVI 14.4M
- Earning Date
- FBIO 11-14-2024
- BIVI 11-13-2024
- Dividend Yield
- FBIO N/A
- BIVI N/A
- EPS Growth
- FBIO N/A
- BIVI N/A
- EPS
- FBIO N/A
- BIVI N/A
- Revenue
- FBIO $81,501,000.00
- BIVI N/A
- Revenue This Year
- FBIO N/A
- BIVI N/A
- Revenue Next Year
- FBIO $81.63
- BIVI N/A
- P/E Ratio
- FBIO N/A
- BIVI N/A
- Revenue Growth
- FBIO 31.51
- BIVI N/A
- 52 Week Low
- FBIO $1.36
- BIVI $1.04
- 52 Week High
- FBIO $4.43
- BIVI $58.20
- Technical
- Relative Strength Index (RSI)
- FBIO 31.19
- BIVI 61.79
- Support Level
- FBIO $1.66
- BIVI $2.87
- Resistance Level
- FBIO $1.79
- BIVI $3.61
- Average True Range (ATR)
- FBIO 0.13
- BIVI 0.35
- MACD
- FBIO -0.04
- BIVI 0.05
- Stochastic Oscillator
- FBIO 2.90
- BIVI 67.19
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.